Breaking News
US is requiring weight-loss drug makers to warn about possible loss of eye sight
Key Points
US is requiring weight-loss drug makers to warn about possible loss of eye sight Close to 30 million Americans are taking the drugs - Bookmark - CommentsGo to comments Become an Independent member to bookmark this article Already a member? Log in The makers of blockbuster weight loss drugs such as Ozempic and Zepbound will be required to include warnings about a rare eye condition that can cause permanent vision loss. Taking GLP-1 drugs carries an increased risk of a condition known as...
US is requiring weight-loss drug makers to warn about possible loss of eye sight
Close to 30 million Americans are taking the drugs
- Bookmark
- CommentsGo to comments
Become an Independent member to bookmark this article
Already a member? Log in
The makers of blockbuster weight loss drugs such as Ozempic and Zepbound will be required to include warnings about a rare eye condition that can cause permanent vision loss.
Taking GLP-1 drugs carries an increased risk of a condition known as “non-arteritic anterior ischemic optic neuropathy,” or NAION, the U.S. Food and Drug Administration said Monday.
Roughly 28 million Americans are taking the drugs, according to a July Gallup poll.
This is a developing story.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments